Serologic Detection of SARS-CoV-2 Infections in Hemodialysis Centers: A Multicenter Retrospective Study in Wuhan, China.

Clicks: 287
ID: 109025
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Patients receiving maintenance hemodialysis (MHD) are highly vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The current study was designed to evaluate the prevalence of SARS-CoV-2 infection based on both nucleic acid testing (NAT) and antibody testing in Chinese patients receiving MHD.Cross-sectional study.From Dec 1, 2019 to Mar 31, 2020, 1027 MHD patients in five large hemodialysis centers in Wuhan, China were enrolled. Patients were screened for SARS-CoV-2 infection by symptoms and initial chest computed tomography (CT). If patients developed symptoms after initial screening was negative, a repeat CT was obtained. Patients suspected of being infected with SARS-CoV-2 were tested with two consecutive throat swabs for viral RNA. In mid-March 2020 antibody testing for SARS-CoV-2 was obtained for all MHD patients.NAT and antibody test results for SARS-CoV-2.Morbidity, clinical features, laboratory and radiologic findings.Differences between groups were examined by Student's t-test or Mann-Whitney U test, comparing those not infected to those infected and comparing those with infection detected by NAT to those with infection detected by positive serology test results.Among 1027 patients receiving MHD, 99 were identified as having SARS-CoV-2 infection, for a prevalence of 9.6%. Among these 99 cases, 52 (53%) were initially diagnosed with SARS-CoV-2 infection by positive NAT; 47 (47%) were identified later by positive IgG or IgM antibodies against SARS-CoV-2. There was a spectrum of antibody profiles in these 47 patients: IgM antibodies in 5 (11%), IgG antibodies in 35 (74%), and both IgM and IgG antibodies in 7 (15%). Of the 99 cases, 51% were asymptomatic during the epidemic; 61% had ground-glass or patchy opacities on chest CT compared to 11.6% among uninfected patients (P<0.001). Patients with hypertensive kidney disease were more often found to have SARS-CoV-2 infection and they were more likely to be symptomatic than patients with another primary cause of kidney failure.Possible false-positive and false-negative results for both NAT and antibody testing; possible lack of generalizability to other dialysis populations.Half of the SARS-CoV-2 infections in patients receiving MHD were subclinical and were not identified by universal chest CT and selective NAT. Serologic testing may help to evaluate the overall prevalence and understand the diversity of clinical courses among patients receiving MHD who are infected with SARS-CoV-2.
Reference Key
tang2020serologicamerican Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tang, Hui;Tian, Jian-Bo;Dong, Jun-Wu;Tang, Xiao-Tie;Yan, Zhen-Yuan;Zhao, Yuan-Yuan;Xiong, Fei;Sun, Xin;Song, Cai-Xia;Xiang, Chang-Gang;Tu, Can;Lei, Chun-Tao;Liu, Jing;Su, Hua;Huang, Jing;Qiu, Yang;Miao, Xiao-Ping;Zhang, Chun;
Journal american journal of kidney diseases : the official journal of the national kidney foundation
Year 2020
DOI
S0272-6386(20)30786-1
URL
Keywords
hemodialysis end-stage kidney disease eskd chronic kidney disease (ckd) pandemic covid-19 sars-cov-2 severe acute respiratory syndrome coronavirus 2 coronavirus disease 2019 asymptomatic infection nat sars-cov-2 infection chest computed tomography dialysis unit disease surveillance infection detection nucleic acid testing serology, antibody testing subclinical infection

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.